[{"id":"1ee7d622-cdd0-4c14-a5ad-ff67b7a251a6","acronym":"NCI-2021-11793","url":"https://clinicaltrials.gov/study/NCT05111561","created_at":"2021-11-08T14:53:11.471Z","updated_at":"2025-02-25T13:40:41.596Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","source_id_and_acronym":"NCT05111561 - NCI-2021-11793","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion","tags":["HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • ZEN-3694"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-21"},{"id":"f7e6df94-a121-41c2-ab20-30322990863a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05327010","created_at":"2022-04-14T12:53:52.597Z","updated_at":"2025-02-25T14:02:49.505Z","phase":"Phase 2","brief_title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","source_id_and_acronym":"NCT05327010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 08/04/2025","primary_completion_date":" 08/04/2025","study_txt":" Completion: 08/04/2025","study_completion_date":" 08/04/2025","last_update_posted":"2025-02-19"},{"id":"0e6f9786-f03c-47e3-82a4-50892d86b673","acronym":"","url":"https://clinicaltrials.gov/study/NCT06102902","created_at":"2023-10-26T15:14:21.567Z","updated_at":"2025-02-25T14:10:15.325Z","phase":"Phase 1","brief_title":"Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer","source_id_and_acronym":"NCT06102902","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/05/2024","start_date":" 06/05/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-17"},{"id":"d94f7980-52bd-4422-b97d-6ffc7470ef49","acronym":"NRG-GY031","url":"https://clinicaltrials.gov/study/NCT05950464","created_at":"2023-07-20T15:09:28.523Z","updated_at":"2025-02-25T14:42:14.385Z","phase":"Phase 1","brief_title":"Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer","source_id_and_acronym":"NCT05950464 - NRG-GY031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZEN-3694 • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-14"},{"id":"64d1ef99-04c4-4d5a-830b-60a55b2be129","acronym":"","url":"https://clinicaltrials.gov/study/NCT05422794","created_at":"2022-06-22T01:54:45.793Z","updated_at":"2025-02-25T16:39:06.146Z","phase":"Phase 1","brief_title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05422794","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • albumin-bound paclitaxel • ZEN-3694 • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/18/2023","start_date":" 05/18/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"5b3bbfcb-81b9-4094-b5ab-f48bff41c08a","acronym":"NCI-2022-04099","url":"https://clinicaltrials.gov/study/NCT05372640","created_at":"2022-05-13T12:54:24.439Z","updated_at":"2025-02-25T16:46:03.280Z","phase":"Phase 1","brief_title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","source_id_and_acronym":"NCT05372640 - NCI-2022-04099","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NUTM1","pipe":"","alterations":" ","tags":["NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-05"},{"id":"1056dca4-95a8-462c-8bb1-1287b2e57c22","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161493","created_at":"2023-12-08T17:16:39.097Z","updated_at":"2025-02-25T13:13:32.183Z","phase":"Phase 1","brief_title":"ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors","source_id_and_acronym":"NCT06161493","lead_sponsor":"Haider Mahdi","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • ZEN-3694"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/23/2024","start_date":" 01/23/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-10-11"},{"id":"70736adb-b060-44c5-baf0-08a2f859c924","acronym":"","url":"https://clinicaltrials.gov/study/NCT04471974","created_at":"2021-01-18T21:29:11.594Z","updated_at":"2025-02-25T16:10:30.954Z","phase":"Phase 2","brief_title":"ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04471974","lead_sponsor":"Rahul Aggarwal","biomarkers":" PD-L1 • RB1","pipe":" | ","alterations":" RB1 deletion • RB deletion","tags":["PD-L1 • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Xtandi (enzalutamide) • ZEN-3694 • ZEN-3219"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-04-26"},{"id":"522c49af-78dd-4744-a59b-263e97c777c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05019716","created_at":"2021-08-25T14:53:05.366Z","updated_at":"2024-07-02T16:35:16.121Z","phase":"Phase 1/2","brief_title":"Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","source_id_and_acronym":"NCT05019716","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRD4 • NUTM1","pipe":"","alterations":" ","tags":["BRD4 • NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"},{"id":"5b5ad733-eb31-4840-89b9-4c48183883d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05607108","created_at":"2022-11-07T13:56:22.739Z","updated_at":"2024-07-02T16:35:24.823Z","phase":"Phase 2","brief_title":"A Study of ZEN003694 in People With Squamous Cell Lung Cancer","source_id_and_acronym":"NCT05607108","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" NSD3","pipe":"","alterations":" ","tags":["NSD3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-01-01"},{"id":"00cc548c-4f04-43c7-b861-7b41b6484b2c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05071937","created_at":"2021-10-08T11:53:52.361Z","updated_at":"2024-07-02T16:35:27.795Z","phase":"Phase 2","brief_title":"ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT05071937","lead_sponsor":"Haider Mahdi","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 04/13/2023","start_date":" 04/13/2023","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2023-11-29"},{"id":"981b6a50-3d41-4dd9-a8d0-e2b7a63da66f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02705469","created_at":"2021-01-18T13:12:32.940Z","updated_at":"2024-07-02T16:37:16.227Z","phase":"Phase 1","brief_title":"A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT02705469","lead_sponsor":"Zenith Epigenetics","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZEN-3694"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 10/01/2017","study_completion_date":" 10/01/2017","last_update_posted":"2017-11-20"}]